<DOC>
	<DOCNO>NCT02613910</DOCNO>
	<brief_summary>This study design multi-country , multicenter , open label extension Phase III trial OPV116910 . The primary objective provide continue treatment ofatumumab subcutaneous ( SC ) eligible subject complete OPV116910 trial order obtain long term safety tolerability information subject pemphigus vulgaris receive ofatumumab SC every 4 week ( wk ) .</brief_summary>
	<brief_title>Long-Term Extension Study Ofatumumab Subjects With Pemphigus Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Pemphigus</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Cetirizine</mesh_term>
	<mesh_term>Histamine Antagonists</mesh_term>
	<mesh_term>Histamine H1 Antagonists</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Adult clinically document diagnosis PV . Completed Study OPV116910 Week 60 one follow outcome : Did achieve remission Week 60 OPV116910 . Achieved remission steroid dose &gt; 10 milligrams/day . Achieved remission minimal steroid therapy , experience disease flare/relapse participate first year ( yr ) OPV116910 Individualized Follow Period ( It recommend subject transition extension study steroid dose increase ) . A woman eligible enter study : Is nonchildbearing potential : document surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy , hysteroscopic tubal occlusion procedure followup confirmation bilateral tubal occlusion ) postmenopausal without menses &gt; 2 year . Women &lt; 2 year postmenopausal require menopausal status confirm folliclestimulating hormone ( FSH ) estradiol level baseline evaluation . If FSH estradiol level provide confirmation menopause , subject consider childbearing potential . Is childbearing potential , negative pregnancy test baseline , agree consistent correct use acceptable method contraception ( HighlyEffective Methods Avoiding Pregnancy ) heterosexual intercourse , begin subject provide informed consent last 12 month last dose ofatumumab SC . Past current history hypersensitivity component investigational product medicallysignificant adverse effect ( include allergic reaction ) cetirizine ( antihistamine equivalent ) paracetamol/acetaminophen . Prior treatment follow within specify period : Medication Other Treatment Restrictions Prior OPV117059 Baseline Any time Ofatumumab ( Intravenous ) , total body irradiation , bone marrow transplantation , anti CD4 ; 6 week Live vaccine 8 week Immunosuppressive immunomodulatory agent , include : azathioprine , cyclosporine , dapsone , mycophenolate , methotrexate , tacrolimus 6 month Cyclophosphamide , cladribine , plasmapheresis , immunoabsorption , immunoglobulin therapy , alemtuzumab , mitoxantrone 18 month Rituximab anti CD20 treatment Confirmed PML neurological finding potentially consistent PML . Evidence history clinically significant infection medical condition include : Chronic ongoing active infectious disease require long term systemic treatment , include , limited , chronic renal infection , chronic chest infection bronchiectasis , active hepatitis C. Positive test hepatitis B surface antigen ( HbsAg ) . For HbsAg negative , hepatitis B core antibody positive ( antiHBc ) ( regardless hepatitis B surface antibody [ HbsAb ] status ) , hepatitis B virus deoxyribonucleic acid ( HBV DNA ) test perform subject exclude result positive . Consult physician experience care management subject hepatitis B manage/treat subject anti HBc positive . Subjects antiHBc positive HBV DNA negative continue monitor throughout study . History positive serology human immunodeficiency virus . Previous serious opportunistic atypical infection . Prior history , suspicion , tuberculosis . A radiograph chest take within 3 month first administration investigational product suggest evidence indicate current active tuberculosis previous tuberculosis . Past current malignancy , except : Cervical carcinoma Stage 1B less ; Noninvasive basal cell squamous cell skin carcinoma ; Cancer diagnose duration complete response ( remission ) &gt; 5 year . Clinical chemistry and/or hematology laboratory value clinical concern , investigator 's opinion . For subject transition directly OPV116910 study , review central chemistry hematology laboratory report Week 48 Week 56 visit OPV116910 . For subject transition Individualized Followup Period OPV116910 , review central chemistry hematology laboratory report recent OPV116910 Individualized Followup visit . If date laboratory report 12 week extension study Screening visit , laboratory assessment need repeat . For subject neutropenia ( absolute neutrophil count &lt; 1 Giga unit per liter , neutropenia must resolve first dose ofatumumab , occur within 4 week screen assessment . Electrocardiogram ( ECG ) show clinically significant abnormality show Corrected QT Interval ( QTc ) interval &gt; =450 millisecond ( msec ) ( &gt; =480 msec subject bundle branch block ) ( ECG obtain Week 60 visit OPV116910 ; Repeat ECG 12 week elapse ) . Significant concurrent , uncontrolled medical condition could affect subject 's safety , impair subject 's reliable participation study , impair evaluation endpoint , necessitate use medication allow protocol . In Investigator 's opinion , reason subject would eligible study ( eg , subject unable comply visit schedule ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Ofatumumab</keyword>
	<keyword>Pemphigus Vulgaris</keyword>
	<keyword>Long-Term Extension Study</keyword>
</DOC>